3 Troubled Stocks Poised To Snap Back: AstraZeneca plc, Rolls-Royce Holding PLC And SABMiller plc

Royston Wild explains why AstraZeneca plc (LON: AZN), Rolls-Royce Holding PLC (LON: RR) and SABMiller plc (LON: SAB) could all be set to blossom.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three blue-chip beauties set to hit the high notes.

AstraZeneca

It is no secret that medicines play AstraZeneca (LSE: AZN) (NYSE: AZN.US) has long been beset by patent expirations across a number of revenues-driving labels.

Exclusivity losses on such products as Symbicort and Seroquel has smashed revenues in recent years, and in February a US court found that the patent for its Pulmicort Respules was invalid, adding to the company’s existing headaches — AstraZeneca was due to lose protection from 2018. The emergence of generic competition for its critical Crestor and Nexium labels are also set to drive group sales steadily lower until end-2016 at the earliest.

Still, AstraZeneca has devoted vast sums to resuscitate its product pipeline, and received a record six approvals in 2014 as a result. And last month the pharma play received positive Phase III trials for its PINNACLE programme designed to combat COPD — the company intends to file for global regulatory approvals this year following this testing.

As well, AstraZeneca also remains hot on the acquisitions trail, and earlier this year purchased Activis’ respiratory business in the US and Canada for $600m plus royalty add-ons. And once the company’s lab-building programme across North America and Europe is complete in the next few years, I expect R&D to really take off at the Cambridge firm and deliver rampant turnover growth.

Rolls-Royce Holding

Diversified engineering play Rolls-Royce (LSE: RR) has suffered a spate of problems over the past year or so. More recently a declining oil price has whacked the outlook for its Marine division, a phenomenon which has forced the company to downgrade its 2015 profits forecasts. And claims of corruption in China and Indonesia have now spread to Brazil, a development which is sure to grab the attention of the Serious Fraud Office which is already investigating dealings at the business.

Of course the prospect of reduced spend from the oil sector is a worry for Rolls-Royce’s top line. But over the long-term, I believe that the Crewe business’ market-leading products across a wide array of industries should underpin terrific earnings growth.

In particular, Rolls-Royce’s top-tier position with the world’s biggest planebuilders should deliver handsome rewards as surging civil aerospace volumes drive demand for its Trent engines, not to mention the firm’s TotalCare maintenance package. Indeed, Rolls-Royce inked a $1bn deal with Air China just last week to power 15 of the carrier’s Boeing Dreamliner aircraft.

With the company’s Aerospace global restructuring drive also bringing it closer to emerging markets and stripping down the cost base — Rolls-Royce announced another 200-odd job cuts in March, on top of the 2,600 posts announced in November — I believe that the firm is in great shape to deliver strong returns in coming years.

SABMiller

Like many of its alcohol sector peers, beer giant SABMiller (LSE: SAB) has been whacked by declining off-take from developing markets, and in particular that of China. Indeed, a 7% decline in net producer revenues (NPR), at constant currencies, from the Asian powerhouse during October-December pushed NPR for the Asia Pacific region 2% lower during the period.

Although SABMiller also saw North American revenues drop 1% in the quarter, strong performance across its other key territories drove group NPR 4% higher during the period. The company’s broad range of beverage labels, which includes Fosters, Peroni and Castle, has helped to drive business in critical Latin American and African marketplaces, and revenues in these places advanced 5% and 7% respectively in the third quarter.

The brewer still faces a huge drag in the form of adverse currency movements — indeed, on a reported basis group NPR actually dropped 5% in October-December. Still, I believe that SABMiller’s vast investment in new territories should deliver handsome earnings expansion on a long-term time horizon on the back of rising personal income levels and booming population growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »